Efficacy of anti-IgE therapy in patients with atopic dermatitis

Vigo, Paul G.; Girgis, Khaled R.; Pfuetze, Bruce L.; Critchlow, M.E.; Fisher, Joe; Hussaın, Iftikhar

doi:10.1016/j.jaad.2005.12.045

Cited by 129 publications

(80 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As mentioned above, it takes 3 months to see an effect with omalizumab. In a similar context, the mean serum IgE levels of the unsuccessful patients were much higher than those in the successful patients 6,9,12 . If the dose of omalizumab is insufficient, then the drug does not thoroughly block all the IgE.…”

Section: Discussionmentioning

confidence: 82%

“…In the unsuccessful cases, although the patients all are adults, omalizumab was administrated at 450 mg subcutaneously every other week for 4 months 6 . However, for the successful cases, most of the patients were children and the dosing was similar to that of the patients of the unsuccessful cases 9,12 .…”

Section: Discussionmentioning

confidence: 83%

“…Some dermatologists have been tried to treat AD patients with omalizumab, and the majority of them were successful in treating AD with omalizumab 9,12 . On the other hand, a few AD patients failed when being treated with omalizumab 6 .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Recalcitrant Atopic Dermatitis Treated with Omalizumab

Park

Choi

et al. 2010

Ann Dermatol

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic cutaneous inflammatory disease. Various categories of therapeutic medications are used for treating AD. Omalizumab is a monoclonal anti-IgE antibody that binds to IgE molecules at the high-affinity receptor (FcεRI) binding site. Therefore, omalizumab can be used as a potential new systemic treatment agent for recalcitrant AD patients with elevated IgE levels. A 34-year-old man had been treated for AD with several topical and oral agents. However, he was refractory to these therapies and his serum IgE levels were very high. We treated him with omalizumab. After 8 months of the treatment, his symptoms were notably improved and the SCORAD index was decreased. Thus, we report on the first case of recalcitrant AD that was successfully treated with omalizumab in Korea. (Ann Dermatol 22(3) 349∼352,

show abstract

Section: Discussionmentioning

confidence: 82%

Section: Discussionmentioning

confidence: 83%

See 1 more Smart Citation

Recalcitrant Atopic Dermatitis Treated with Omalizumab

Park

Choi

et al. 2010

Ann Dermatol

View full text Add to dashboard Cite

show abstract

“…AD were associated with other allergic disorders such as asthma and allergic rhinitis (AR) in all patients (Table 1). All patients had taken Xolair subcutaneously (SC) (3,(8)(9)(10)(11)(12)(13)(14).…”

Section: Resultsmentioning

confidence: 99%

“…The duration of treatment was different from 12 weeks, 20 weeks, 24 weeks, and 12 to 67 months (9,(11)(12)(13). Serum IgE level decreased in 100% of the studies (3,(8)(9)(10)(11)(12)(13)(14). It seems that Xolair could be effective in decreasing IgE levels in different doses and durations of the treatment, although, the decrease of IgE level is not important on its own.…”

Section: Discussionmentioning

confidence: 97%

Omalizumab (Xolair) in Children with Atopic Dermatitis: A Review Article

Ghaffari

2017

J Pediatr Rev

View full text Add to dashboard Cite

Context: Atopic dermatitis is a chronic skin disease in children. The prevalence of eczema is up to 30% in the world. Omalizumab (Xolair) is a monoclonal antibody that blocks the serum IgE. The aim of this study is to review the effect of Xolair in children with atopic dermatitis. Evidence Acquisition: The data was searched in PubMed, Scopus, and Embase with keywords: atopic dermatitis, eczema, children, pediatrics, Xolair, and Omalizumab. The inclusion criteria included articles related to use of Xolair in children with atopic dermatitis, under the age of 20 years old, as well a both full text and brief articles. The exclusion criteria were purely adult cases who had taken systemic immunosuppressive drugs and abstract article. There was no time limitation for our search. Results: After evaluating all data and a total of 124 searched articles, we found 8 eligible articles for this review. All of them had severe atopic dermatitis except 2 cases, which had moderate severity. Serum IgE level was increased in all patients. Only one of those studies included a control group. All patients were associated with other allergic disorders such as asthma and allergic rhinitis. Conclusions: Omalizumab (Xolair) is a safe drug, which decreases serum IgE level, scoring atopic dermatitis, as well as clinical manifestations in all of severe atopic dermatitis. However, in order to approve it, we need future clinical trial studies with control group.

show abstract